These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Yearly zoledronic acid in postmenopausal osteoporosis. de Nijs RN; Westgeest AA N Engl J Med; 2007 Aug; 357(7):711; author reply 714-5. PubMed ID: 17699824 [No Abstract] [Full Text] [Related]
6. A once-yearly IV bisphosphonate for osteoporosis. Obstet Gynecol; 2008 May; 111(5):1208-9. PubMed ID: 18448761 [No Abstract] [Full Text] [Related]
7. Yearly zoledronic acid in postmenopausal osteoporosis. Karam R; Camm J; McClung M N Engl J Med; 2007 Aug; 357(7):712-3; author reply 714-5. PubMed ID: 17703529 [No Abstract] [Full Text] [Related]
8. Consultation corner. Bone loss drug gives users a break. Bellantoni M Johns Hopkins Med Lett Health After 50; 2007 Dec; 19(10):6. PubMed ID: 18225340 [No Abstract] [Full Text] [Related]
9. Boning up on osteoporosis medications. Johns Hopkins Med Lett Health After 50; 2010 May; 22(3):1-2, 7. PubMed ID: 20518136 [No Abstract] [Full Text] [Related]
10. To treat osteoporosis, Denosumab appears more effective than Zoledronate. Denosumab has the advantage in building bone density, and has fewer side effects. Duke Med Health News; 2014 Mar; 20(3):1-2. PubMed ID: 24683617 [No Abstract] [Full Text] [Related]
11. Giant cell arteritis with visual loss following zoledronic acid infusion. Metyas S; Ibrahim M; Solyman J; Yeter KC; Arkfeld DG Int J Rheum Dis; 2014 Jan; 17(1):113-5. PubMed ID: 24472274 [TBL] [Abstract][Full Text] [Related]
12. By the way, doctor. Should I take an intravenous drug for osteoporosis? Robb-Nicholson C Harv Womens Health Watch; 2007 Jul; 14(11):8. PubMed ID: 17665505 [No Abstract] [Full Text] [Related]
13. Oral bisphosphonates and atrial fibrillation. Majumdar SR BMJ; 2008 Apr; 336(7648):784-5. PubMed ID: 18334526 [TBL] [Abstract][Full Text] [Related]
14. New annual osteoporosis drug reduces risk of death, future fractures. Infused dose is more convenient for patients, enhances overall quality of life. Duke Med Health News; 2007 Dec; 13(12):8. PubMed ID: 18286732 [No Abstract] [Full Text] [Related]
16. Avascular necrosis of the proximal carpal row of the wrist. A possible complication of bisphosphonate administration. Didden K; De Smet L; Vandenberghe L; Sciot R; Degreef I Chir Main; 2012 Dec; 31(6):355-7. PubMed ID: 23177907 [TBL] [Abstract][Full Text] [Related]
17. [New bone density conservation agents for osteoporosis under research and development: Zoledronate]. Wada S; Fukawa T; Kamiya S Nihon Rinsho; 2007 Nov; 65 Suppl 9():421-5. PubMed ID: 18161143 [No Abstract] [Full Text] [Related]
18. A once-yearly IV bisphosphonate for osteoporosis. Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523 [No Abstract] [Full Text] [Related]
19. Zoledronic acid and osteonecrosis of the jaw: incidence varies with use. Wynn RL Gen Dent; 2011; 59(5):330-2. PubMed ID: 22313815 [No Abstract] [Full Text] [Related]
20. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis. Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]